Skip to content

Vieworks Co., Ltd.

Request correction

South Korean imaging technology company making digital X-ray detectors, industrial machine-vision cameras, and bioimaging systems.

Last updated September 26, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

Vieworks is a South Korean imaging technology company headquartered in Anyang-si, Gyeonggi-do, whose name combines "View" and "Works" to signal its focus on imaging solutions. According to its own corporate narrative, it has spent more than two decades developing high-performance imaging systems for global markets, specializing in three main lines: digital X-ray detectors for medical and industrial radiography, industrial cameras for machine vision, and bioimaging systems for life-science research. Its products are sold under brands such as VIVIX (X-ray detectors), VXvue (digital radiography acquisition software), VISQUE (digital pathology scanners and in vivo imaging systems), and VEO (industrial lenses). The company organizes its business into three reported segments — X-ray Imaging, Machine Vision, and Bio Imaging — and serves medical, industrial, and life-science customers. Its X-ray portfolio includes static and dynamic digital detectors, with certifications such as FDA clearance for the VIVIX-M and VIVIX-S series and CE MDR certification for additional static detectors. In machine vision, Vieworks supplies area and line scan cameras, including TDI line scan cameras that were designated a World Class Product in 2025, and industrial lenses. In bio imaging, it has commercialized digital pathology scanners and preclinical in vivo imaging systems, and has embedded AI into slide-scanning workflows. Vieworks is a publicly traded company on the KOSDAQ market in South Korea, and its disclosures reference KOSDAQ Awards for Technology Development Excellence and repeated selections as a KOSDAQ Rising Star. It reports financial results publicly; its own news feed cites 2025 revenue of 239.3 billion won, up 7.4%, and a first-half operating profit of 19.5 billion won, up 127.4%. The company has expanded internationally, establishing Vieworks South America Ltd in 2024, and maintains a global network of sales and support. It also operates a Hwaseong site that has undergone expansion, and a Pangyo Laboratory established in 2022. Strategically, Vieworks positions itself as more than a manufacturer — a long-term imaging partner — emphasizing R&D, differentiated technology, and product quality. It invests in talent development and describes a culture built on passion, creativity, and morality, with a self-driven organizational structure. Its recent public communications highlight AI-integrated imaging solutions, next-generation machine vision, and digital pathology automation, indicating a push toward higher-value, software- and AI-enabled imaging platforms alongside its core hardware.

History

Vieworks was founded in 1999, according to the company's own history timeline, and has since grown into a publicly traded imaging technology specialist on South Korea's KOSDAQ market. Its name, a combination of "View" and "Works," reflects a stated commitment to delivering imaging solutions that contribute meaningfully to society. Over more than two decades it has developed high-performance imaging systems for global markets, specializing in digital X-ray detectors, industrial cameras, and bioimaging systems. The company's early history is presented on its website as a year-by-year timeline beginning in 1999. Through the 2000s and 2010s it built out its three core business lines. In X-ray imaging, it developed digital detectors for medical and industrial radiography, later adding acquisition software such as VXvue. In machine vision, it produced industrial cameras and lenses, including TDI line scan cameras. In bio imaging, it developed digital pathology scanners and preclinical in vivo imaging systems under the VISQUE brand. A series of dated milestones illustrates its trajectory. In 2021, Vieworks commercially launched industrial lenses in the VEO series and launched what it describes as the world's first 152-megapixel (or similar high-resolution) camera, and it won a Red Dot Design Award 2021 for the VIVIX-S F series. In 2022, it commercially launched the preclinical in vivo imaging system VISQUE in vivo Art series, established the Vieworks Pangyo Laboratory, obtained FDA certification for the VIVIX-S F series, and was selected as a 2022 KOSDAQ Rising Star by the Korea Exchange (KRX). In 2023, it won an iF Design Award 2023 for the VIVIX-S F series, acquired shares in CSI System Co., Ltd., was selected as a 2023 KOSDAQ Rising Star, and commenced expansion of its Hwaseong site. In 2024, it established Vieworks South America Ltd, was selected as a 2024 KOSDAQ Rising Star, obtained MFDS certification for VXCAD-CXR (an AI-aided diagnostic solution), and obtained FDA certification for the VIVIX-S 1751S. In 2025, it obtained FDA certification for the VIVIX-M series, acquired shares of NVisage Technologies, LLC, completed the expansion of the Vieworks Hwaseong Site, obtained CE IVDR certification for the VISQUE DPS (Digital Pathology Scanner), obtained FDA certification for VXvue (Digital Radiography Acquisition Software), had its TDI line scan cameras designated as a World Class Product, obtained CE MDR certification for the VIVIX-S F Series, 1751S, and 4386W, and won the KOSDAQ Awards for Technology Development Excellence. Financially, Vieworks reports publicly as a listed company. Its own news feed cites 2025 revenue of 239.3 billion won, up 7.4% year on year, and a first-half operating profit of 19.5 billion won, up 127.4%. It has also disclosed a Corporate Value-Up Plan and reported first-quarter results for 2026. The company continues to expand its global footprint, with a South American subsidiary and participation in international trade shows such as ECR, USCAP, Vision China Shanghai, and AW. Its recent emphasis is on AI-integrated imaging solutions, digital pathology workflow automation, and next-generation machine vision.

  • 2025

    FDA certified VIVIX-M Series; acquired shares of NVisage Technologies, LLC; completed expansion of Vieworks Hwaseong Site; CE IVDR certified VISQUE DPS; FDA certified VXvue; TDI line scan cameras designated as World Class Product; CE MDR certified VIVIX-S F Series, 1751S, 4386W; won KOSDAQ Awards for Technology Development Excellence.

  • 2024

    Established Vieworks South America Ltd; selected as 2024 KOSDAQ Rising Star; MFDS certified VXCAD-CXR (AI-aided diagnostic solution); FDA certified VIVIX-S 1751S.

  • 2023

    Awarded iF Design Award 2023 for VIVIX-S F series; acquired shares in CSI System Co., Ltd.; selected as 2023 KOSDAQ Rising Star; commenced expansion of Hwaseong Site.

  • 2022

    Commercially launched preclinical in vivo imaging system VISQUE in vivo Art series; established Vieworks Pangyo Laboratory; FDA certified VIVIX-S F series; selected as 2022 KOSDAQ Rising Star by KRX.

  • 2021

    Commercially launched industrial lenses: VEO series; launched world's first 152-megapixel-class camera; won Red Dot Design Award 2021 for VIVIX-S F series.

  • 1999

    Vieworks founded (per company history timeline).

Products and positioning

A long-term imaging partner providing high-performance, AI-integrated imaging solutions across medical, industrial, and life-science applications.

  • VIVIX series digital X-ray detectors

    Static and dynamic digital detectors for medical and industrial radiography; models include VIVIX-M, VIVIX-S F series, VIVIX-S 1751S, and 4386W.

  • VXvue digital radiography acquisition software

    Software for acquiring and processing digital radiography images; FDA certified in 2025.

  • VISQUE digital pathology scanner (DPS)

    Slide scanner for pathology workflows; CE IVDR certified in 2025; AI embedded to advance workflow automation; VISQUE DPS LH210 supports both cytology and histology.

  • VISQUE in vivo imaging systems

    Preclinical in vivo imaging systems; VISQUE in vivo Art series commercially launched in 2022.

  • VEO series industrial lenses

    Industrial lenses for machine vision, commercially launched in 2021.

  • TDI line scan cameras

    Time Delayed Integration line scan cameras for machine vision; designated a World Class Product in 2025.

  • VXCAD-CXR

    AI-aided diagnostic solution; MFDS certified in 2024.

Sources4 sources

Cite this profile: Cite the canonical profile. /brand-wiki/vieworks · Editorial policy · How profiles are compiled